Biogen Inc (BIIB)

Biogen Inc. is a biotechnology company whose common stock is listed on NASDAQ under the symbol BIIB. The company discovers, develops, manufactures, and delivers therapies for patients in the United States, Europe, Germany, Asia, and other international markets. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, amyotrophic lateral sclerosis, plaque psoriasis, Alzheimer’s disease, postpartum depression, and several B-cell related cancers and autoimmune conditions. Biogen’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, SPINRAZA, SKYCLARYS, QALSODY, LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and other anti-CD20 therapies, along with select biosimilars. The company also maintains collaboration and licensing relationships with multiple biopharmaceutical partners, including Eisai, UCB, Genentech, Ionis, Samsung Bioepis, and Sage Therapeutics. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen remains focused on neurological and related therapeutic areas.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.